Tuesday, shares of Oculis Holding AG (NASDAQ:OCS), currently trading at $17.65 and near its 52-week high of $18.10, may see market reactions after H.C. Wainwright analyst reaffirmed a Buy rating and a $30.00 price target.
According to InvestingPro, the stock has shown remarkable momentum with a 51.37% gain over the past six months. Chen’s endorsement follows the recent announcement of successful Phase 2 trial results for Oculis’s OCS-05, a potential treatment for acute optic neuritis (AON).
The ACUITY trial, a randomized, double-blind, placebo-controlled study conducted in France, achieved its primary safety endpoints and key secondary efficacy endpoints. Chen highlighted the significance of OCS-05, an activator of serum glucocorticoid kinase-2 (SGK-2), noting its potential as a neuroprotective treatment that could protect nerve axons.
With a market capitalization of $740.33 million, Oculis maintains strong liquidity with a current ratio of 4.02, indicating solid financial positioning for its drug development programs.
AON, typically affecting adults between 20 to 40 years old, impacts up to 8 in 100,000 people globally. Currently, there is no approved therapy for AON. Steroids are commonly used to address inflammation associated with the condition but fail to prevent subsequent vision loss.
The positive results from the ACUITY study are seen as supportive for advancing OCS-05 into a Phase 2b trial in the United States. The U.S. FDA has already cleared an Investigational New Drug (IND) application for OCS-05, which has also received Orphan Drug designation, a status that could provide certain advantages for the drug’s development.
Chen expressed optimism for the upcoming U.S. trial, anticipating that the company might initiate the Phase 2b trial in 2025. Given these developments, H.C. Wainwright’s reiteration of the Buy rating and $30 price target reflects confidence in Oculis’s progress and potential market opportunity.
InvestingPro analysis suggests the stock is currently trading above its Fair Value, with analyst targets ranging from $22.01 to $35.73. Subscribers can access 13 additional ProTips and comprehensive financial metrics to make more informed investment decisions.
In other recent news, Oculis Holding AG has been making notable strides in its development programs. The company recently reported promising results from a study on its OCS-05 treatment for acute optic neuritis (AON). The treatment showed significant improvement in both anatomical and functional vision, suggesting potential applications for other conditions that cause optic nerve damage, including multiple sclerosis.
Stifel analysts have maintained their Buy rating and a $35.00 price target for Oculis, following these encouraging study results. This rating comes as the ACUITY trial, which tested the safety and efficacy of OCS-05, successfully met its primary and secondary endpoints. The trial demonstrated significant improvement in ganglion cell and retinal nerve thickness compared to a placebo.
Following these positive outcomes, the FDA granted an Investigational New Drug (IND) clearance for OCS-05. This clearance allows Oculis to commence registrational development of the treatment for AON, marking a significant regulatory milestone for the company.
In addition to this, Oculis is expanding its research and development efforts, exploring additional formulations of OCS-05 to potentially offer neuroprotection in chronic conditions such as glaucoma and diabetic retinopathy. These recent developments highlight Oculis’ commitment to addressing conditions with limited therapeutic options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
